Clinical trial
Guideline for the Treatment of Newly Diagnosed Patients Eith Acutypromyelocytic Leukemia, Aged > 12 Months (1 Year) and <75 Years, Using All-trans Retinoic Acid in Combination With Idarubicin
NCT01064557 is registered in ClinicalTrials.gov with Gruppo Italiano Malattie EMatologiche dell'Adulto as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Guideline for the Treatment of Newly Diagnosed Patients Eith Acutypromyelocytic Leukemia, Aged > 12 Months (1 Year) and <75 Years, Using All-trans Retinoic Acid in Combination With Idarubicin
- Lead sponsor
- Gruppo Italiano Malattie EMatologiche dell'Adulto
- Phase
- Not applicable
- Overall status
- Unknown status
- Start date
- October 31, 1993
- Completion date
- December 31, 2020
- Enrollment
- 1,068 (estimated)
- Sites
- 80
Conditions
As the registry lists them; a condition with its own page is linked.